Hwang Shin, Park Kwang-Min, Lee Sung-Gyu, Sung Kyu-Bo, Lee Young-Joo, Choi Dong-Nak, Ahn Chul-Soo, Min Pyung-Chul
Department of General Surgery, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Poongnap-dong, Songpa-gu, Seoul, 138-736, Korea.
Hepatogastroenterology. 2002 Nov-Dec;49(48):1669-72.
We report two cases of transjugular intrahepatic portosystemic shunt for control of intractable ascites after resection of cirrhotic livers. The first case was a 46-year-old male who had undergone right lobectomy of the liver for a small hepatocellular carcinoma. His liver function had recovered within a week after the operation, but ascites drainage of 1-4 L/day persisted for more than a month despite vigorous medical therapy. We performed transjugular intrahepatic portosystemic shunt on the 49th postoperative day and the pressure gradient between the right atrium and the left portal vein was reduced to from 21 mmHg to 6 mmHg. Thereafter, ascites became responsive to diuretic therapy and was well controlled without complication. Second case of a 54-year-old male patient who had undergone left lateral segmentectomy due to a small hepatocellular carcinoma presented intractable ascites of 1-3 L/day, which was also effectively controlled after transjugular intrahepatic portosystemic shunt performed on the 34th postoperative day, though there was an episode of hepatic encephalopathy stage 1. Based on our limited experience, hepatectomized patients suffering from prolonged intractable ascites despite a favorable profile of liver function may be candidates for transjugular intrahepatic portosystemic shunt with an acceptable risk of hepatic failure and procedure-related complication.
我们报告两例经颈静脉肝内门体分流术治疗肝硬化肝脏切除术后顽固性腹水的病例。第一例是一名46岁男性,因小肝细胞癌接受了肝右叶切除术。术后一周内其肝功能恢复,但尽管积极进行药物治疗,每天仍有1 - 4升腹水持续引流超过一个月。我们在术后第49天进行了经颈静脉肝内门体分流术,右心房与左门静脉之间的压力梯度从21 mmHg降至6 mmHg。此后,腹水对利尿剂治疗有反应,得到良好控制且无并发症。第二例是一名54岁男性患者,因小肝细胞癌接受了肝左外叶切除术,术后出现每天1 - 3升的顽固性腹水,在术后第34天进行经颈静脉肝内门体分流术后也得到有效控制,不过出现了1期肝性脑病。基于我们有限的经验,尽管肝功能状况良好,但仍患有长期顽固性腹水的肝切除患者可能是经颈静脉肝内门体分流术的候选者,且肝衰竭和手术相关并发症的风险可接受。